To determine whether packed red blood cell transfusions through small-bore central venous catheters used in critically ill neonates results in significant hemolysis.In vitro experimental study using a mock transfusion setup incorporating a syringe pump, prestorage leukoreduced fresher, and older CPDA-1 red blood cell units and pressure transducer simulating neonatal transfusion through 1.9-Fr NeoPICC central venous catheter.Laboratory setting.None.None.Spun hematocrit, plasma free hemoglobin (hemoglobin), lactate dehydrogenase, and potassium were analyzed pretransfusion, at various times during transfusion, and posttransfusion. Intraluminal pressures were measured using a TruWave Disposable Pressure Transducer. Using fresher (5-8 days old) and older (29-30 days old) CPDA-1 red blood cells, we compared 2 and 20 mL/hr flow rates. Statistical analysis was performed using repeated measures of analysis of variance to compare the differences in means between flow rates. Mean intraluminal pressures at the end of each experiment were significantly higher at 20 mL/hr flow rates (>360 mm Hg) in both fresher and older red blood cells than at 2 mL/hr (range, 61-70 mm Hg). Overall, potassium, lactate dehydrogenase, and plasma free hemoglobin concentrations were significantly higher for older red blood cells at either 2 or 20 mL/hr (p<.001). Both fresher and older red blood cells demonstrated higher potassium concentrations at 20 mL/hr (22.4%, p<.001;0.7%, p>.05, respectively); however, these increases were not clinically significant. Furthermore, lactate dehydrogenase, hematocrit, and plasma free hemoglobin differences seen at 2 and 20 mL/hr did not coincide with changes in potassium.No clinically significant hemolysis was evidenced with red blood cell transfusion through small-bore central venous catheters when using fresher or older CPDA-1 red blood cells at 2 or 20 mL/hr.
Intercenter variation exists in the management of hypoxic-ischemic encephalopathy (HIE). It is unclear whether increased resource utilization translates into improved neurodevelopmental outcomes.To determine if higher resource utilization during the first 4 days of age, quantified by hospital costs, is associated with survival without neurodevelopmental impairment (NDI) among infants with HIE.Retrospective cohort analysis of neonates with HIE who underwent therapeutic hypothermia (TH) at US children's hospitals participating in the Children's Hospitals Neonatal Database between 2010 and 2016. Data were analyzed from December 2021 to December 2022.Infants who survived to 4 days of age and had neurodevelopmental outcomes assessed at greater than 11 months of age were divided into 2 groups: (1) death or NDI and (2) survived without NDI. Resource utilization was defined as costs of hospitalization including neonatal neurocritical care (NNCC). Data were linked with Pediatric Health Information Systems to quantify standardized costs by terciles.The main outcome was death or NDI. Characteristics, outcomes, hospitalization, and NNCC costs were compared.Among the 381 patients who were included, median (IQR) gestational age was 39 (38-40) weeks; maternal race included 79 (20.7%) Black mothers, 237 (62.2%) White mothers, and 58 (15.2%) mothers with other race; 80 (21%) died, 64 (17%) survived with NDI (combined death or NDI group: 144 patients [38%]), and 237 (62%) survived without NDI. The combined death or NDI group had a higher rate of infants with Apgar score at 10 minutes less than or equal to 5 (65.3% [94 of 144] vs 39.7% [94 of 237]; P < .001) and a lower rate of infants with mild or moderate HIE (36.1% [52 of 144] vs 82.3% [195 of 237]; P < .001) compared with the survived without NDI group. Compared with low-cost centers, there was no association between high- or medium-hospitalization cost centers and death or NDI. High- and medium-EEG cost centers had lower odds of death or NDI compared with low-cost centers (high vs low: OR, 0.30 [95% CI, 0.16-0.57]; medium vs low: OR, 0.29 [95% CI, 0.13-0.62]). High- and medium-laboratory cost centers had higher odds of death or NDI compared with low-cost centers (high vs low: OR, 2.35 [95% CI, 1.19-4.66]; medium vs low: OR, 1.93 [95% CI, 1.07-3.47]). High-antiseizure medication cost centers had higher odds of death or NDI compared with low-cost centers (high vs. low: OR, 3.72 [95% CI, 1.51-9.18]; medium vs low: OR, 1.56 [95% CI, 0.71-3.42]).Hospitalization costs during the first 4 days of age in neonates with HIE treated with TH were not associated with neurodevelopmental outcomes. Higher EEG costs were associated with lower odds of death or NDI yet higher laboratory and antiseizure medication costs were not. These findings serve as first steps toward identifying aspects of NNCC that are associated with outcomes.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
